Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Adiponectin rs2241766T/G and rs17300593G/A rather than rs1501299G/T and rs266729C/G polymorphisms were associated with the risk of DN in T2DM, especially in the Caucasian population.
|
24825737 |
2015 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study aims to evaluate the association of the ACDC genetic variation in T1D and diabetic nephropathy (DN).
|
17189871 |
2007 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association of 18 ADIPOQ polymorphisms with DN in a prospective Taiwanese cohort of type 2 diabetes (T2D) and explored whether gender plays a role in this genetic association.
|
24894086 |
2014 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of adiponectin in the development of diabetic nephropathy has not been elucidated, and the aim of the present study was to investigate the hypothesis that deletion of the gene for adiponectin would accelerate diabetic nephropathy in the Akita mouse.
|
25957229 |
2015 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, adiponectin over-expression in STZ rats decreased markers of endothelial dysfunction, a feature of diabetic nephropathy disease progression.
|
21521713 |
2011 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to investigate the possible association of ADIPOQ gene polymorphisms with T2DM and/or DN and whether they affect serum adiponectin levels in Egyptian population.
|
24469713 |
2014 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study provides evidence that MCF2L2, ADIPOQ and SOX2 genetic polymorphisms have effects on the resistance of DN in female T1D patients, and suggests that the linkage with DN in chromosome 3q may be explained by the cumulated genetic effects.
|
20667095 |
2010 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The overall significance for this variant (nominal P = 0.011) suggests that ADIPOQ might be involved in the development of diabetic nephropathy.
|
17065357 |
2006 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we identified the binding sites for transcriptional factors in the adiponectin promoter region and also evaluated the association between adiponectin promoter polymorphisms and diabetic nephropathy (DN) in T1D patients.
|
18599322 |
2009 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We performed a case-control study to examine whether the SNP276 of the adiponectin gene was also related to early diabetic nephropathy.
|
15334388 |
2004 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Abnormal expression and dysfunction of adiponectin and the cognate receptors are involved in diabetes and diabetic kidney disease (DKD), whereas angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) alleviate diabetic albuminuria and prevent development of DKD through upregulation of adiponectin expression.
|
28870804 |
2017 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to investigate the therapeutic effects and the underlying mechanisms of adiponectin in early DN.
|
24816832 |
2014 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The minor allele of rs3865188 was associated with lower adiponectin levels (P = 0.006). rs11646213 [odds ratio (OR) 1.47; 95% confidence interval (CI) 1.18-1.85; P = 0.0009] and rs3865188 (OR 0.71; 95% CI 0.57-0.90; P = 0.004) were associated with baseline prevalence of established/advanced DN.
|
28499019 |
2017 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results indicate that 11 genetic variants within or near VEGFA, CCR5, CCL2, IL-1, MMP9, EPO, IL-8, ADIPOQ and IL-10 showed significant positive association with diabetic nephropathy.
|
25280384 |
2014 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin exhibits its biological effects through adiponectin receptors (AdipoR1 and AdipoR2), which are distributed in the kidneys, and activation of those receptors could prevent or ameliorate diabetic nephropathy.
|
30135333 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Urinary adiponectin as a new diagnostic index for chronic kidney disease due to diabetic nephropathy.
|
31245009 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We propose AdipoRon, an orally active synthetic adiponectin receptor agonist as a promising drug for restoration of DKD without inducing systemic adverse effects.
|
30974901 |
2019 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study aims to examine the association of tumor necrosis factor-α (TNF-α) g.-308 G > A and adiponectin (ADIPOQ) g. + 45 T > G gene polymorphisms in type 2 diabetes (T2D) and its microvascular complications diabetic retinopathy (DR) and diabetic nephropathy (DN).
|
24655058 |
2014 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin improves diabetic nephropathy by inhibiting necrotic apoptosis.
|
31572480 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy.
|
18496510 |
2008 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin (ADP) may hold promise as a biomarker for diabetic nephropathy (DN).
|
30557306 |
2018 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, there was an association between ADIPOQ -11391A allele with increased DN risk (OR = 1.186, 95% CI: 1.051-1.338, p = 0.006).
|
24344808 |
2014 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Renin-angiotensin-aldosterone system blockers, adiponectin receptor agonists, and PPAR agonists (e.g., tesaglitazar, thiazolidinediones, fenofibrate), which increase plasma adiponectin levels and adiponectin receptors expression, may be potential therapeutic drugs for the treatment of DKD.
|
28402446 |
2017 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The LPD prevented the progression of diabetic status; this effect may have been associated with the reduction of FW and the elevation of plasma FGF21 and HMW adiponectin, as well as UCP1 expression in BAT, resulting in suppression of diabetic nephropathy.
|
29507597 |
2018 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes.
|
29330340 |
2018 |